Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Question-and-Answer SessionSo let's start out with a bit of a big picture. Can you remind us of any notable pushes and pulls throughout the year in terms of both revenue and OpEx we should be considering?Adam LenkowskyExecutive VP & Chief Commercialization Officer Yes, happy to do that. When I take a step back, when you think about 2025 performance, we delivered strong performance and execution. And so we had good momentum coming into 2026, particularly with our growth portfolio. So products like Reblozyl, ...